HHT combined with a Bcl-2 inhibitor antagonizes the FLT3-STAT5 pathway by downregulating the expression of Bcl-2 and Mcl-1 (203) and also interferes with the PI3K/AKT/GSK3β pathway to effectively treat leukemia (204). The gene discussed is BCL2; the disease is leukemia.